Tenax Therapeutics (TENX) Accounts Payables (2011 - 2026)
Tenax Therapeutics recorded quarterly Accounts Payables of $6.3 million in Q1 2026, up 5.05% quarter-over-quarter from $6.0 million in Q4 2025, and up 245.08% year-over-year from $1.8 million in Q1 2025.
Tenax Therapeutics' Accounts Payables history runs 15 years deep, the most recent figure standing at $6.3 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 245.08% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $6.3 million (up 245.08% YoY), while the FY2025 annual figure was $6.0 million, up 91.35% from the prior year.
- Accounts Payables came in at $6.3 million for Q1 2026 at Tenax Therapeutics, up from $6.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $6.3 million in Q1 2026 to a low of $206459.0 in Q2 2023.
- A 5-year average of $1.9 million and a median of $919384.0 in 2022 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables slumped 77.54% in 2023 and soared 440.74% in 2024, its largest moves.
- Tenax Therapeutics' Accounts Payables stood at $775045.0 in 2022, then jumped by 167.47% to $2.1 million in 2023, then surged by 52.29% to $3.2 million in 2024, then surged by 91.35% to $6.0 million in 2025, then increased by 5.05% to $6.3 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $6.3 million, $6.0 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | 6.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.35 Mn |
| Dec 31, 2025 | 6.04 Mn |
| Sep 30, 2025 | 5.61 Mn |
| Jun 30, 2025 | 562,000.00 |
| Mar 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 869,656.00 |
| Mar 31, 2024 | 536,443.00 |
| Dec 31, 2023 | 2.07 Mn |
| Sep 30, 2023 | 292,961.00 |
| Jun 30, 2023 | 206,459.00 |
| Mar 31, 2023 | 307,922.00 |
| Dec 31, 2022 | 775,045.00 |
| Sep 30, 2022 | 265,407.00 |
| Jun 30, 2022 | 919,384.00 |
| Mar 31, 2022 | 1.29 Mn |
| Dec 31, 2021 | 859,638.00 |
| Sep 30, 2021 | 776,247.00 |
| Jun 30, 2021 | 791,947.00 |
| Mar 31, 2021 | 997,443.00 |
| Dec 31, 2020 | 757,856.00 |
| Sep 30, 2020 | 1.05 Mn |
| Jun 30, 2020 | 1.56 Mn |
| Mar 31, 2020 | 1.81 Mn |
| Dec 31, 2019 | 1.66 Mn |
| Sep 30, 2019 | 225,523.00 |
| Jun 30, 2019 | 448,824.00 |
| Mar 31, 2019 | 596,809.00 |
| Dec 31, 2018 | 749,814.00 |
| Sep 30, 2018 | 392,482.00 |
| Jun 30, 2018 | 203,153.00 |
| Mar 31, 2018 | 189,558.00 |
| Dec 31, 2017 | 611,861.00 |
| Sep 30, 2017 | 579,386.00 |
| Jun 30, 2017 | 434,195.00 |
| Mar 31, 2017 | 1.40 Mn |
| Dec 31, 2016 | 727,599.00 |
| Sep 30, 2016 | 1.39 Mn |
| Jun 30, 2016 | 1.52 Mn |
| Dec 31, 2015 | 972,483.00 |
| Apr 30, 2013 | 977,162.00 |
| Jan 31, 2013 | 807,679.00 |
| Oct 31, 2012 | 479,300.00 |
| Jul 31, 2012 | 835,100.00 |
| Apr 30, 2012 | 542,809.00 |
| Jan 31, 2012 | 650,351.00 |
| Oct 31, 2011 | 781,509.00 |
| Jul 31, 2011 | 1.06 Mn |
| Apr 30, 2011 | 889,376.00 |